Study on Optimizing the Treatment of Patients With Acute Myeloid Leukemia Based on Early Peripheral Blood Minimal Residual Disease

This study is testing whether checking for cancer cells in the blood early during treatment can help doctors adjust chemotherapy to improve outcomes for newly diagnosed patients with acute myeloid leukemia (AML), a type of blood cancer. **You may be eligible if...** - You are 18 or older - You have been newly diagnosed with AML (confirmed by bone marrow tests) - You have had full diagnostic testing including genetic and chromosomal analysis - Your blood test on day 6 of treatment shows at least 1% blast cells (immature cancer cells) - Your kidney and liver function are adequate - Your doctor has determined you are suitable for standard chemotherapy **You may NOT be eligible if...** - You have a specific subtype of AML called acute promyelocytic leukemia (APL) - Your AML has mixed features (mixed phenotype acute leukemia) - Your cancer has spread to the brain or nervous system - You have cancer outside the bone marrow (extramedullary disease) - You have severe kidney or liver dysfunction Talk to your doctor to see if this trial is right for you.